Business Context and Reporting Period
This Form 8-K is a current report filed by vTv Therapeutics Inc. on March 30, 2022. The registrant is incorporated in Delaware and its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT. The report addresses a specific corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the departure of a director:
- Mr. Noel Spiegel, who served as a director and Chair of the Audit Committee since the company's 2015 IPO, notified the company of his decision not to stand for re-election at the 2022 annual meeting of stockholders.
- The filing explicitly states that this decision was not due to any disagreement regarding the company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, financial outlook, management commentary on future performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Confirm the status of the Audit Committee Chair position following Mr. Spiegel's departure.
- Verify if a replacement director has been nominated for the 2022 annual meeting.
- Review the company's most recent 10-K or 10-Q for financial health, as this 8-K contains no financial data.